In our previous study, we found that Tim-3 was preferentially expressed in lymphoma-derived endothelial cells and suppressed activation of CD4+ T lymphocytes through the activation of the interleukin-6–STAT3 pathway. The gene discussed is HAVCR2; the disease is lymphoma.